@article{5ebe7d46f8c748089ccfb449370e02a2,
title = "Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma",
abstract = "Objective Intrahepatic cholangiocarcinoma (ICC) - a rare liver malignancy with limited therapeutic options - is characterised by aggressive progression, desmoplasia and vascular abnormalities. The aim of this study was to determine the role of placental growth factor (PlGF) in ICC progression. Design We evaluated the expression of PlGF in specimens from ICC patients and assessed the therapeutic effect of genetic or pharmacologic inhibition of PlGF in orthotopically grafted ICC mouse models. We evaluated the impact of PlGF stimulation or blockade in ICC cells and cancer-associated fibroblasts (CAFs) using in vitro 3-D coculture systems. Results PlGF levels were elevated in human ICC stromal cells and circulating blood plasma and were associated with disease progression. Single-cell RNA sequencing showed that the major impact of PlGF blockade in mice was enrichment of quiescent CAFs, characterised by high gene transcription levels related to the Akt pathway, glycolysis and hypoxia signalling. PlGF blockade suppressed Akt phosphorylation and myofibroblast activation in ICC-derived CAFs. PlGF blockade also reduced desmoplasia and tissue stiffness, which resulted in reopening of collapsed tumour vessels and improved blood perfusion, while reducing ICC cell invasion. Moreover, PlGF blockade enhanced the efficacy of standard chemotherapy in mice-bearing ICC. Conclusion PlGF blockade leads to a reduction in intratumorous hypoxia and metastatic dissemination, enhanced chemotherapy sensitivity and increased survival in mice-bearing aggressive ICC.",
keywords = "cholangiocarcinoma, hepatic fibrosis",
author = "Shuichi Aoki and Koetsu Inoue and Sebastian Klein and Stefan Halvorsen and Jiang Chen and Aya Matsui and Nikmaneshi, {Mohammad R.} and Shuji Kitahara and Tai Hato and Xianfeng Chen and Kazumichi Kawakubo and Nia, {Hadi T.} and Ivy Chen and Schanne, {Daniel H.} and Emilie Mamessier and Kohei Shigeta and Hiroto Kikuchi and Ramjiawan, {Rakesh R.} and Schmidt, {Tyge C.E.} and Masaaki Iwasaki and Thomas Yau and Hong, {Theodore S.} and Alexander Quaas and Plum, {Patrick S.} and Simona Dima and Irinel Popescu and Nabeel Bardeesy and Munn, {Lance L.} and Borad, {Mitesh J.} and Slim Sassi and Jain, {Rakesh K.} and Zhu, {Andrew X.} and Duda, {Dan G.}",
note = "Funding Information: Funding DD{\textquoteright}s work was supported through NIH grants P01-CA080124, R41-CA213678 and Proton Beam/Federal Share Programme and Department of DefenseDefence grants #W81XWH-19-1-0284 and W81XWH-19-1-0482. RKJ{\textquoteright}s work was supported through NIH grants P01-CA080124, R35-CA197743, R01-CA208205 and U01-CA224173, and by the National Foundation for Cancer Research, Harvard Ludwig Cancer Centre, Advanced Medical Research Foundation and Jane{\textquoteright}s Trust Foundation. IP{\textquoteright}s work was supported by the Romanian Ministry of Research and Innovation, CCCDI–UEFISCDI, project number PN-III-P1-1.2-PCCDI-2017-0797/66PCCDI, within PNCDI III. SA{\textquoteright}s research was supported by a Postdoctoral Fellowship from Cholangiocarcinoma Research Foundation, TH received a Postdoctoral Fellowship from Astellas Foundation for Research on Metabolic Disorders, Japan, DS received a Postdoctoral Fellowship from Humboldt Foundation, KS received a Postdoctoral Fellowship from Uehara Memorial Foundation, and EM received a grant from the Philippe Foundation and the Canc{\'e}rop{\^o}le PACA. Funding Information: Competing interests IC is an employee of STIMIT. TY has served in a consulting or advisory role for Bristol Myers Squibb. RKJ received honorarium from Amgen and consultant fees from Chugai, Ophthotech, Merck, SPARC, SynDevRx. RKJ owns equity in Accurius, Enlight, SPARC, and SynDevRx, and serves on the Boards of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund. AXZ is a consultant/advisory board member for Bayer. DGD received consultant fees from Bayer, Simcere, Surface Oncology and BMS and research grants from Bayer, Exelixis and BMS. No reagents or support from these companies was used for this study. Publisher Copyright: {\textcopyright} Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",
year = "2022",
month = jan,
day = "1",
doi = "10.1136/gutjnl-2020-322493",
language = "English",
volume = "71",
pages = "185--193",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "1",
}
